Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on April 6, 2006, regarding events occurring on March 31, 2006. The filing discloses the entry into a material definitive agreement and the creation of a direct financial obligation.
Key Financial Metrics
The filing details a new debt facility rather than operational financial performance metrics such as revenue or profit.
- Total Borrowing: Approximately $387,700 borrowed from Oxford Finance Corporation.
- Debt Structure:
- $240,500 at a fixed interest rate of 10.07%, repayable in 48 monthly installments.
- $147,200 at a fixed interest rate of 10.09%, repayable in 36 monthly installments.
- Repayment Commencement: Monthly principal and interest payments began on March 31, 2006.
- Collateral: Alnylam granted Oxford a security interest in all property financed by the lender.
Material Changes
The primary material change is the establishment of a revolving credit facility via a Master Security Agreement with Oxford Finance Corporation, allowing for future borrowings in addition to the initial drawdown of $387,700.
Outlook, Risks, and Contingencies
The filing identifies a specific contingency regarding default. If an event of default occurs as defined in the Security Agreement, Oxford Finance Corporation has the right to declare any or all debts, obligations, and liabilities immediately due and payable. The filing does not provide management commentary on future revenue, product pipeline, or broader market outlook.
Investor Verification Checklist
- Verify the total outstanding debt balance and repayment schedule in subsequent quarterly filings (10-Q).
- Review the full text of the Master Security Agreement (Exhibit 10.1) for specific definitions of "event of default."
- Monitor future borrowings under the Master Security Agreement to assess total leverage.
- Confirm the impact of the 10%+ interest rates on the company's cash flow projections.